tuberculosis vaccines

Summary

Summary: Vaccines or candidate vaccines used to prevent or treat TUBERCULOSIS.

Top Publications

  1. pmc Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals
    Clare R Sander
    Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, University of Oxford, Oxford OX3 7LJ, UK
    Am J Respir Crit Care Med 179:724-33. 2009
  2. ncbi IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge
    Shabaana A Khader
    Trudeau Institute, Saranac Lake, New York 12983, USA
    Nat Immunol 8:369-77. 2007
  3. ncbi Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants
    Thomas J Scriba
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, University of Cape Town, South Africa
    J Infect Dis 203:1832-43. 2011
  4. pmc Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells
    Thomas J Scriba
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, University of Cape Town, Observatory, South Africa
    Eur J Immunol 40:279-90. 2010
  5. ncbi Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti
    Alexander S Pym
    Unite de Genetique Moleculaire Bacterienne, Institut Pasteur, 28 rue du Docteur Roux, 75724 Paris, Cedex 15, France
    Mol Microbiol 46:709-17. 2002
  6. ncbi A multistage tuberculosis vaccine that confers efficient protection before and after exposure
    Claus Aagaard
    Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark
    Nat Med 17:189-94. 2011
  7. pmc A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults
    Thomas J Scriba
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa
    Am J Respir Crit Care Med 185:769-78. 2012
  8. ncbi Tuberculosis vaccines: time to think about the next generation
    Stefan H E Kaufmann
    Max Planck Institute for Infection Biology, Department of Immunology, Berlin, Germany
    Semin Immunol 25:172-81. 2013
  9. pmc Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics
    Laith J Abu-Raddad
    Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Proc Natl Acad Sci U S A 106:13980-5. 2009
  10. pmc Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
    Ansar A Pathan
    The Jenner Institute, University of Oxford, Oxford, United Kingdom
    Vaccine 30:5616-24. 2012

Research Grants

Detail Information

Publications293 found, 100 shown here

  1. pmc Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals
    Clare R Sander
    Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, University of Oxford, Oxford OX3 7LJ, UK
    Am J Respir Crit Care Med 179:724-33. 2009
    ..An effective new tuberculosis (TB) vaccine regimen must be safe in individuals with latent TB infection (LTBI) and is a priority for global health care...
  2. ncbi IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge
    Shabaana A Khader
    Trudeau Institute, Saranac Lake, New York 12983, USA
    Nat Immunol 8:369-77. 2007
    ....
  3. ncbi Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants
    Thomas J Scriba
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, University of Cape Town, South Africa
    J Infect Dis 203:1832-43. 2011
    ..We assessed the safety of and characterized the T cell response induced by 3 doses of the candidate vaccine, MVA85A, in BCG-vaccinated infants from a setting where tuberculosis is endemic...
  4. pmc Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells
    Thomas J Scriba
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, University of Cape Town, Observatory, South Africa
    Eur J Immunol 40:279-90. 2010
    ..This includes induction of novel Th1-cell populations that have not been previously described in humans...
  5. ncbi Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti
    Alexander S Pym
    Unite de Genetique Moleculaire Bacterienne, Institut Pasteur, 28 rue du Docteur Roux, 75724 Paris, Cedex 15, France
    Mol Microbiol 46:709-17. 2002
    ..Knocking-in five other RD loci did not affect the virulence of BCG. This study describes a genetic lesion that contributes to safety and opens new avenues for vaccine development...
  6. ncbi A multistage tuberculosis vaccine that confers efficient protection before and after exposure
    Claus Aagaard
    Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark
    Nat Med 17:189-94. 2011
    All tuberculosis vaccines currently in clinical trials are designed as prophylactic vaccines based on early expressed antigens...
  7. pmc A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults
    Thomas J Scriba
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa
    Am J Respir Crit Care Med 185:769-78. 2012
    ..Novel tuberculosis (TB) vaccines should be safe and effective in populations infected with Mycobacterium tuberculosis (M.tb) and/or HIV for effective TB control...
  8. ncbi Tuberculosis vaccines: time to think about the next generation
    Stefan H E Kaufmann
    Max Planck Institute for Infection Biology, Department of Immunology, Berlin, Germany
    Semin Immunol 25:172-81. 2013
    ..Qualitatively superior vaccines should be capable of preventing or eliminating Mtb infection, in this way eliminating the risk of TB reactivation. The time is now ripe to exploit radically new strategies to achieve this goal. ..
  9. pmc Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics
    Laith J Abu-Raddad
    Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Proc Natl Acad Sci U S A 106:13980-5. 2009
    ..Elimination will require new delivery strategies, such as mass vaccination campaigns, and new products targeted at latently infected people...
  10. pmc Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
    Ansar A Pathan
    The Jenner Institute, University of Oxford, Oxford, United Kingdom
    Vaccine 30:5616-24. 2012
    ....
  11. pmc Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel Mycobacterium tuberculosis vaccine MVA85A
    Kristin L Griffiths
    The Jenner Institute, Oxford University, Oxford, United Kingdom
    PLoS ONE 6:e23463. 2011
    ..These results suggest a relationship between extracellular ATP and effector responses and unveil a possible pathway that could be targeted during vaccine design...
  12. pmc The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection
    Philana Ling Lin
    Department of Pediatrics, Children s Hospital of Pittsburgh of University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
    J Clin Invest 122:303-14. 2012
    ..Our results indicate that H56/IC31 boosting is able to control late-stage infection with M. tuberculosis and contain latent tuberculosis, providing a rationale for the clinical development of H56...
  13. pmc Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis
    H Martin Vordermeier
    TB Research Group, VLA Weybridge, New Haw, Addlestone, Surrey, United Kingdom
    Infect Immun 77:3364-73. 2009
    ..These findings also have implications for human tuberculosis vaccine development...
  14. ncbi New vaccines for tuberculosis
    Stefan H E Kaufmann
    Department of Immunology, Max Planck Institute for Infection Biology, Berlin, Germany
    Lancet 375:2110-9. 2010
    ..Long-term vaccination strategies need to target these more ambitious goals. Even though vaccine development will have a price, the return of investment will greatly exceed original costs...
  15. ncbi Recombinant live vaccine candidates against tuberculosis
    Stefan H E Kaufmann
    Max Planck Institute for Infection Biology, Department of Immunology, Chariteplatz 1, 10117 Berlin, Germany
    Curr Opin Biotechnol 23:900-7. 2012
    ....
  16. pmc MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques
    Frank A W Verreck
    Department of Parasitology, Biomedical Primate Research Centre, Rijswijk, The Netherlands
    PLoS ONE 4:e5264. 2009
    ..Relevant models are required to downselect the most promising vaccines entering clinical efficacy testing and to identify correlates of protection...
  17. ncbi Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells
    Thomas Lindenstrøm
    Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark
    J Immunol 182:8047-55. 2009
    ....
  18. ncbi Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection
    Jaap T van Dissel
    Leiden University Medical Center LUMC, Department of Infectious Diseases, Leiden, The Netherlands j t van
    Vaccine 29:2100-9. 2011
    ..The strong responses persisted through 32 weeks of follow-up, indicating the induction of a persistent memory response in the vaccine recipients...
  19. pmc Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcRgamma-Syk-Card9-dependent innate immune activation
    Kerstin Werninghaus
    Institute of Medical Microbiology, Immunology and Hygiene, Technical University Munich, D 81675 Munich, Germany
    J Exp Med 206:89-97. 2009
    ..These data provide a molecular basis for the immunostimulatory activity of TDB and TDM and identify the Syk-Card9 pathway as a rational target for vaccine development against tuberculosis...
  20. pmc Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis
    Sylvie Bertholet
    Infectious Disease Research Institute, Seattle WA 98104, USA
    J Immunol 181:7948-57. 2008
    ..This study identified numerous novel human T cell Ags suitable to be included in subunit vaccines against tuberculosis...
  21. ncbi Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis
    Jun Wang
    Department of Pathology and Molecular Medicine and Division of Infectious Diseases, Centre for Gene Therapeutics, McMaster University, 1200 Main Street West, Hamilton, Ontario, Canada L8N 3Z5
    J Immunol 173:6357-65. 2004
    ..Our study also lends strong evidence that respiratory mucosal vaccination is critically advantageous over systemic routes of vaccination against TB...
  22. ncbi Future vaccination strategies against tuberculosis: thinking outside the box
    Stefan H E Kaufmann
    Department of Immunology, Max Planck Institute for Infection Biology, Chariteplatz 1, D 10117 Berlin, Germany
    Immunity 33:567-77. 2010
    ..Here, we review current and future strategies toward the rational design of novel vaccines against TB, as well as the progress made thus far, and the hurdles that need to be overcome in the near and distant future...
  23. pmc Tuberculosis vaccines: beyond bacille Calmette-Guerin
    Helen McShane
    The Jenner Institute, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK
    Philos Trans R Soc Lond B Biol Sci 366:2782-9. 2011
    ..This article reviews the leading candidate vaccines in development and considers the current challenges in the field with regard to efficacy testing...
  24. pmc Preclinical evidence for implementing a prime-boost vaccine strategy for tuberculosis
    Michael J Brennan
    Aeras, Rockville, MD 20850, USA
    Vaccine 30:2811-23. 2012
    ....
  25. ncbi Airway delivery of soluble mycobacterial antigens restores protective mucosal immunity by single intramuscular plasmid DNA tuberculosis vaccination: role of proinflammatory signals in the lung
    Mangalakumari Jeyanathan
    Centre for Gene Therapeutics, M G DeGroote Institute for Infectious Disease Research, and Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
    J Immunol 181:5618-26. 2008
    ..Our study holds implication for the future design of DNA vaccination strategies against intracellular infections...
  26. ncbi Recent findings in immunology give tuberculosis vaccines a new boost
    Stefan H E Kaufmann
    Max Planck Institute for Infection Biology, Department of Immunology, Schumannstrasse 21 22, 10117 Berlin, Germany
    Trends Immunol 26:660-7. 2005
    ..For clinical trials, biomarkers need to be defined with T cells alternating between lung and periphery as prime indicator cells...
  27. pmc Genome plasticity of BCG and impact on vaccine efficacy
    Roland Brosch
    Unite de Genetique Moleculaire Bacterienne, Institut Pasteur, 28 rue du Docteur Roux, 75724 Paris Cedex 15, France
    Proc Natl Acad Sci U S A 104:5596-601. 2007
    ..Furthermore, the combined findings suggest that early BCG vaccines may even be superior to the later ones that are more widely used...
  28. ncbi Quality and vaccine efficacy of CD4+ T cell responses directed to dominant and subdominant epitopes in ESAT-6 from Mycobacterium tuberculosis
    Claus Sindbjerg Aagaard
    Department of Infectious Immunology, Statens Serum Institute, Copenhagen, Denmark
    J Immunol 183:2659-68. 2009
    ....
  29. ncbi Poor immunogenicity of BCG in helminth infected population is associated with increased in vitro TGF-beta production
    Daniel Elias
    Armauer Hansen Research Institute, Addis Ababa, Ethiopia
    Vaccine 26:3897-902. 2008
    ..14). The data presented here demonstrate that chronic worm infection reduces the immunogenicity of BCG in humans and this was associated with increased TGF-beta production but not with enhanced Th2 immune response...
  30. pmc Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa
    Roger H Brookes
    Bacterial Diseases Programme, Tuberculosis Division, Medical Research Council Laboratories, Fajara, Banjul, The Gambia
    PLoS ONE 3:e2921. 2008
    ..We assessed the safety and immunogenicity of this new vaccine in West African volunteers...
  31. ncbi Vaccine-induced anti-tuberculosis protective immunity in mice correlates with the magnitude and quality of multifunctional CD4 T cells
    Steven C Derrick
    Laboratory of Mycobacterial Diseases and Cellular Immunology, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Bethesda, MD 20892, United States
    Vaccine 29:2902-9. 2011
    ..These data support efforts to use MFT cell analyses as a measure of TB vaccine immunogenicity in human immunization studies...
  32. pmc The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults
    Brian Abel
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, UCT Health Sciences, Anzio Road, Observatory 7925, Cape Town, South Africa
    Am J Respir Crit Care Med 181:1407-17. 2010
    ..AERAS-402 is a novel tuberculosis vaccine designed to boost immunity primed by bacillus Calmette-Guérin (BCG), the only licensed vaccine...
  33. ncbi Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen
    Yasir A W Skeiky
    Aeras Global TB Vaccine Foundation, Rockville, MD 20850, USA
    Vaccine 28:1084-93. 2010
    ..Therefore, all non-clinical data supports the suitability of HyVac4 as a safe, immunogenic, and effective vaccination in a prime-boost regimen with BCG...
  34. ncbi Tuberculosis vaccine research: the impact of immunology
    Lewellys F Barker
    Aeras Global TB Vaccine Foundation, Rockville, MD 20850, USA
    Curr Opin Immunol 21:331-8. 2009
    ....
  35. ncbi An update on vaccines for tuberculosis - there is more to it than just waning of BCG efficacy with time
    Marta Romano
    Scientific Institute of Public Health WIV ISP Site Ukkel, Program Host Pathogen Interactions, Service Immunology, Brussels, Belgium
    Expert Opin Biol Ther 12:1601-10. 2012
    ..Apart from better diagnostics and new anti-microbial drugs, an effective vaccine for tuberculosis is urgently needed to halt this poverty-related disease, afflicting millions of people worldwide...
  36. ncbi Alteration of epitope recognition pattern in Ag85B and ESAT-6 has a profound influence on vaccine-induced protection against Mycobacterium tuberculosis
    Thomas Bennekov
    Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark
    Eur J Immunol 36:3346-55. 2006
    ....
  37. ncbi The next 10 years for tuberculosis vaccines: do we have the right plans in place?
    Joel Meyer
    The Jenner Institute, Old Road Campus Research Building, Roosevelt Drive, Oxford, OX3 7DQ, UK
    Expert Rev Vaccines 12:443-51. 2013
    ..Moreover, the increasing pace, extent and coordination of global research efforts in TB promises to broaden understanding and inform the next generation of vaccine candidates against TB as well as related globally important pathogens...
  38. pmc Vaccine-induced th17 cells are maintained long-term postvaccination as a distinct and phenotypically stable memory subset
    Thomas Lindenstrøm
    Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark
    Infect Immun 80:3533-44. 2012
    ..tuberculosis-infected lung. In the absence of overt inflammation, however, stable bona fide Th17 memory can indeed be induced by parenteral immunization...
  39. ncbi A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants
    A A Odutola
    Vaccinology Theme, Medical Research Council Unit, Banjul, The Gambia
    Vaccine 30:5591-4. 2012
    ..All the children had negligible evidence of latent infection with M. tuberculosis (Mtb), suggesting that deploying a prophylactic vaccine against Mtb infection at this age could still be effective in this setting...
  40. ncbi Production of a fusion protein consisting of the enterotoxigenic Escherichia coli heat-labile toxin B subunit and a tuberculosis antigen in Arabidopsis thaliana
    M M Rigano
    Department of Biology, University of Milan, Milan, Italy
    Plant Cell Rep 22:502-8. 2004
    ..Both components of the fusion protein were detected using GM1-ganglioside-dependent enzyme-linked immunosorbant assay. This suggested the fusion protein retained both its native antigenicity and the ability to form pentamers...
  41. ncbi A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity
    Daniel F Hoft
    Division of Infectious Diseases, Allergy and Immunology, Departments of Internal Medicine and Molecular Microbiology, Saint Louis University Medical Center and Center for Vaccine Development, Saint Louis, MO 63104, USA
    Vaccine 30:2098-108. 2012
    ..Despite the availability of Bacille Calmette Guérin (BCG) vaccines, Mycobacterium tuberculosis currently infects billions of people and millions die annually from tuberculosis (TB) disease. New TB vaccines are urgently needed...
  42. pmc The importance of adjuvant formulation in the development of a tuberculosis vaccine
    Susan L Baldwin
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    J Immunol 188:2189-97. 2012
    ..These results highlight the importance of properly formulating subunit vaccines with effective adjuvants for use against tuberculosis...
  43. pmc Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin
    David J M Lewis
    St George s Vaccine Institute, St George s University of London, London, United Kingdom
    PLoS ONE 4:e6999. 2009
    ..The individual component(s) responsible for paralysis were not identified, and the vaccine was withdrawn...
  44. ncbi Immune responses to tuberculosis in developing countries: implications for new vaccines
    Graham A W Rook
    Centre for Infectious Diseases and International Health, Windeyer Institute for Medical Sciences, University College London, London W1T 4JF, UK
    Nat Rev Immunol 5:661-7. 2005
    ..We propose that a successful vaccine needs to block this immunopathology, because it is not the quantity of T(H)1-cell activity that matters but, rather, its context...
  45. ncbi Improved CD4⁺ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial
    Isabel Leroux-Roels
    Center for Vaccinology, Ghent University Hospital, Ghent, Belgium
    Vaccine 31:2196-206. 2013
    ....
  46. ncbi Use of recombinant virus-vectored tuberculosis vaccines for respiratory mucosal immunization
    Zhou Xing
    Infectious Diseases Division, Centre for Gene Therapeutics and Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ont, Canada
    Tuberculosis (Edinb) 86:211-7. 2006
    ..We have also recently developed a recombinant vesicular stomatitis virus-vectored (VSV) TB vaccine. Ad and VSV vector systems will be complementary to each other for BCG prime-virus vaccine boost immunization protocols...
  47. pmc Mycobacterium tuberculosis peptides presented by HLA-E molecules are targets for human CD8 T-cells with cytotoxic as well as regulatory activity
    Simone A Joosten
    Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands
    PLoS Pathog 6:e1000782. 2010
    ..Our results significantly increase our understanding of the human immune response to Mtb by identification of CD8(+) T-cell responses to novel HLA-E binding peptides of Mtb, which have cytotoxic as well as immunoregulatory activity...
  48. ncbi Nanoparticle-based adjuvant for enhanced protective efficacy of DNA vaccine Ag85A-ESAT-6-IL-21 against Mycobacterium tuberculosis infection
    Fangliu Yu
    Department of Pathogenic Biology and Immunology, Medical School, Southeast University, Nanjing, China
    Nanomedicine 8:1337-44. 2012
    ..tuberculosis in the mice. These findings highlighted the potential utility of Fe3O4-Glu-polyethyleneimine nanoparticles encapsulated with the DNA vaccine as a prophylactic vaccine in the M. tuberculosis-infected mouse model...
  49. ncbi Extraordinarily few organisms of a live recombinant BCG vaccine against tuberculosis induce maximal cell-mediated and protective immunity
    Marcus A Horwitz
    Department of Medicine, CHS 37 121, School of Medicine, University of California Los Angeles, 10833 Le Conte Ave, Los Angeles, CA 90095 1688, USA
    Vaccine 24:443-51. 2006
    ..This study demonstrates that a very low inoculum of rBCG30 organisms has the capacity to induce strong protective immunity against tuberculosis and that rBCG30 is an extremely potent delivery system for mycobacterial antigens...
  50. ncbi Towards new tuberculosis vaccines
    Stefan Svenson
    Department of Clinical Research and Education, South Hospital, Karolinska Institutet, Stockholm, Sweden
    Hum Vaccin 6:309-17. 2010
    ..The live attenuated Bacillus Calmette-Guérin (BCG) vaccine which is the only currently available TB vaccine does not confer any significant protection against the most common and contagious form of TB-adult pulmonary TB...
  51. ncbi Do successful tuberculosis vaccines need to be immunoregulatory rather than merely Th1-boosting?
    Graham A W Rook
    Centre for Infectious Disease and International Health, University College London, Windeyer Institute of Medical Sciences, London W1T 4JF, UK
    Vaccine 23:2115-20. 2005
    ..A successful vaccine, rather than driving a Th1 response, might need to suppress this pre-existing subversive Th2-like component...
  52. pmc Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon
    Katarina Radosevic
    Crucell Holland BV, Archimedesweg 4 6, 2333 CN Leiden, The Netherlands
    Infect Immun 75:4105-15. 2007
    ..These results unify conflicting reports on the relative importance of CD4 versus CD8 T-cell responses in protection and emphasize the key role of IFN-gamma...
  53. ncbi Novel prophylactic and therapeutic vaccine against tuberculosis
    Masaji Okada
    Clinical Research Center, National Hospital Organization Kinki chuo Chest Medical Center, 1180 Nagasone, Kitaku, Sakai, Osaka 591 8555, Japan
    Vaccine 27:3267-70. 2009
    ..These data indicate that our novel DNA vaccine might be useful against Mycobacterium tuberculosis including XDR-TB and MDR-TB for human therapeutic clinical trials...
  54. pmc The Apa protein of Mycobacterium tuberculosis stimulates gamma interferon-secreting CD4+ and CD8+ T cells from purified protein derivative-positive individuals and affords protection in a guinea pig model
    Priti Kumar
    Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, Karnataka 560012, India
    Infect Immun 71:1929-37. 2003
    ....
  55. pmc Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A
    Kathryn T Whelan
    Jenner Institute, University of Oxford, Churchill Hospital, Oxford, United Kingdom
    PLoS ONE 4:e5934. 2009
    ....
  56. pmc Investigating the induction of vaccine-induced Th17 and regulatory T cells in healthy, Mycobacterium bovis BCG-immunized adults vaccinated with a new tuberculosis vaccine, MVA85A
    Simone C de Cassan
    The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Headington, Oxford OX3 7DQ, United Kingdom
    Clin Vaccine Immunol 17:1066-73. 2010
    ..These data highlight the intricate balance of effector and regulatory immune responses induced by vaccination and that preexisting immunity to mycobacterial antigens may affect the composition of vaccine-induced T-cell subsets...
  57. pmc Tuberculosis vaccines in clinical trials
    Rosalind Rowland
    The Jenner Institute, Old Road Campus Research Building, Oxford University, Oxford, OX3 7DQ, UK
    Expert Rev Vaccines 10:645-58. 2011
    ..There is a great need for validated animal models, identification of immunological biomarkers of protection and field sites with the capacity for large-scale efficacy testing in order to develop and license a novel TB vaccine or regimen...
  58. pmc Efficacy and safety of live attenuated persistent and rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primates
    Michelle H Larsen
    Albert Einstein College of Medicine, Bronx, NY 1461, USA
    Vaccine 27:4709-17. 2009
    ..BCG vaccinates had reduced tuberculosis-associated pathology and improved clinical scores as compared to saline and mc(2)6030 vaccinates, but survival did not differ among the groups...
  59. ncbi Mycobacterium tuberculosis arabinomannan-protein conjugates protect against tuberculosis
    Beston Hamasur
    Swedish Institute for Infectious Disease Control, S 17182 Solna, Sweden
    Vaccine 21:4081-93. 2003
    ..In guinea-pigs, immunization with AMOs-Ag85B in Eurocine L3 adjuvant followed by aerogenic challenge with M. tuberculosis H37Rv resulted in increased survival and reduced pathology in lungs and spleens relative to non-immunized animals...
  60. pmc Evaluation of the Mtb72F polyprotein vaccine in a rabbit model of tuberculous meningitis
    Liana Tsenova
    Laboratory of Mycobacterial Immunity and Pathogenesis, The Public Health Research Institute, 225 Warren Street, Newark, NJ 07103, USA
    Infect Immun 74:2392-401. 2006
    ..Interestingly, Mtb72F+AS01B induced better protection against leukocytosis and weight loss, suggesting that the polyprotein in this adjuvant may boost immunity without exacerbating inflammation in previously BCG-vaccinated individuals...
  61. pmc Immunological diversity within a family of cutinase-like proteins of Mycobacterium tuberculosis
    Nicholas P West
    Mycobacterial Research Program, Centenary Institute of Cancer Medicine and Cell Biology Locked Bag 6, Newtown, NSW 2042, Australia
    Vaccine 26:3853-9. 2008
    ..Finally, following delivery of DNA vaccines, Clp1, 2 and 6, conferred a moderate yet reproducible and significant level of protection in a murine aerosol model of M. tuberculosis infection...
  62. ncbi Update on research and development pipeline: tuberculosis vaccines
    Belinda Beresford
    Aeras Global TB Vaccine Foundation, Rockville, Maryland 20850, USA
    Clin Infect Dis 50:S178-83. 2010
    ....
  63. pmc Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding
    Eung Jun Im
    Weatherall Institute of Molecular Medicine, University of Oxford, The John Radcliffe, Oxford OX3 9DS, United Kingdom
    J Virol 81:9408-18. 2007
    ....
  64. ncbi Interaction of Mycobacterium tuberculosis with the host: consequences for vaccine development
    Jes Dietrich
    Department of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark
    APMIS 117:440-57. 2009
    ..In this review, we will discuss what is presently known about the interaction of M. tuberculosis with the immune system, and how this knowledge is used in new and more advanced vaccine strategies...
  65. ncbi Half-truths and selective memory: Interferon gamma, CD4(+) T cells and protective memory against tuberculosis
    Lisa Goldsack
    Malaghan Institute of Medical Research, P O Box 7060, Wellington South 6021, New Zealand
    Tuberculosis (Edinb) 87:465-73. 2007
    ..A comprehensive understanding of the requirements for protective memory immunity to tuberculosis is essential for the development of an effective vaccine...
  66. pmc The protective role of antibody responses during Mycobacterium tuberculosis infection
    F Abebe
    University of Oslo, Faculty of Medicine, Institute of General Practice and Community Medicine, Section for International Health, Oslo, Norway
    Clin Exp Immunol 157:235-43. 2009
    ....
  67. ncbi A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis
    Vasan K Sambandamurthy
    Howard Hughes Medical Institute and Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA
    Nat Med 8:1171-4. 2002
    ..Our findings highlight the importance of de novo pantothenate biosynthesis in limiting the intracellular survival and pathogenesis of M. tuberculosis without reducing its immunogenicity in vaccinated mice...
  68. pmc DNA polymorphisms in the pepA and PPE18 genes among clinical strains of Mycobacterium tuberculosis: implications for vaccine efficacy
    Andrea M Hebert
    Epidemiology Department, School of Public Health, University of Michigan, 109 S Observatory Street, Ann Arbor, MI 48109 2029, USA
    Infect Immun 75:5798-805. 2007
    ..Thus, immunity induced by Mtb72F may not recognize a proportion of M. tuberculosis clinical strains...
  69. ncbi Mycobacterium tuberculosis DeltaRD1 DeltapanCD: a safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis
    Vasan K Sambandamurthy
    Department of Microbiology and Immunology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, United States
    Vaccine 24:6309-20. 2006
    ..tuberculosis. Given its overall safety and effectiveness, the mc(2)6030 live attenuated strain should be considered as a human vaccine candidate for protecting both healthy and HIV-infected individuals against TB...
  70. ncbi Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein
    Yasir A W Skeiky
    Corixa Corp, Seattle, WA 98104, USA
    J Immunol 172:7618-28. 2004
    ..tuberculosis comparable to bacillus Calmette-Guérin immunization. Mtb72F in AS02A formulation is currently in phase I clinical trial, making it the first recombinant tuberculosis vaccine to be tested in humans...
  71. ncbi Murine airway luminal antituberculosis memory CD8 T cells by mucosal immunization are maintained via antigen-driven in situ proliferation, independent of peripheral T cell recruitment
    Mangalakumari Jeyanathan
    Centre for Gene Therapeutics, M G DeGroote Institute for Infectious Disease Research, Hamilton, Ontario L8N 3Z5, Canada
    Am J Respir Crit Care Med 181:862-72. 2010
    ..However, the mechanisms of their maintenance on airway mucosal surface still remain poorly understood...
  72. ncbi Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans
    Helen McShane
    Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford, OX3 7LJ, UK
    Nat Med 10:1240-4. 2004
    ..Boosting vaccinations with MVA85A could offer a practical and efficient strategy for enhancing and prolonging antimycobacterial immunity in tuberculosis-endemic areas...
  73. pmc Interactions of attenuated Mycobacterium tuberculosis phoP mutant with human macrophages
    Nadia L Ferrer
    Grupo de Genética de Micobacterias, Departamento de Microbiologia, Medicina Preventiva y Salud Pública, Universidad de Zaragoza, Zaragoza, Spain
    PLoS ONE 5:e12978. 2010
    ....
  74. pmc Immunogenicity and protective efficacy of tuberculosis DNA vaccines combining mycolyl-transferase Ag85A and phosphate transport receptor PstS-3
    Marta Romano
    Mycobacterial Immunology, Pasteur Institute, Wetenschappelijk Instituut voor Volksgezondheid, Brussels, Belgium
    Immunology 118:321-32. 2006
    ..This may have implications for future combination vaccines using Ag85...
  75. pmc CD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination
    Tara Elvang
    Department of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark
    PLoS ONE 4:e5139. 2009
    ..tb in fact involves both CD4 and CD8 T cells. To test this, we used a new vaccine strategy that generated a strong balanced T cell response consisting of both CD4 and CD8 T cells...
  76. ncbi Prospects for elimination of childhood tuberculosis: the role of new vaccines
    Mark Hatherill
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, and School of Child and Adolescent Health, Faculty of Health Sciences, University of Cape Town, Room 2 10, Wernher Beit North, Anzio Road, Cape Town 7925, South Africa
    Arch Dis Child 96:851-6. 2011
    ..14 new tuberculosis vaccines have entered human clinical trials, including viral-vectored vaccines, recombinant fusion proteins, ..
  77. ncbi Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants
    Martin O C Ota
    Bacterial Diseases Programme, Medical Research Council Unit, P O Box 273, Banjul, The Gambia
    Sci Transl Med 3:88ra56. 2011
    New tuberculosis vaccines are urgently needed to curtail the current epidemic. MVA85A is a subunit vaccine that could enhance immunity from BCG vaccination...
  78. ncbi Tuberculosis vaccines: progress and challenges
    Anna M Checkley
    Jenner Institute, Nuffield Department of Medicine, Oxford University, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, UK
    Trends Pharmacol Sci 32:601-6. 2011
    ..Following this, large efficacy trials are undertaken, which face the daunting challenges of cost, logistics and trial site capacity...
  79. ncbi DIVA reagents for bovine tuberculosis vaccines in cattle
    Martin Vordermeier
    Animal Health and Veterinary Laboratories Agency, Weybridge, TB Research Group, New Haw, Addlestone, Surrey KT15 3NB, UK
    Expert Rev Vaccines 10:1083-91. 2011
    ..We also discuss the possible cost-effective application of DIVA tests within the remits of a cattle BCG vaccine program...
  80. pmc A human challenge model for Mycobacterium tuberculosis using Mycobacterium bovis bacille Calmette-Guerin
    Angela M Minassian
    The Jenner Institute, University of Oxford, UK
    J Infect Dis 205:1035-42. 2012
    ..In vivo antimycobacterial immunity could be assessed using intradermal Mycobacterium bovis bacille Calmette-Guérin (BCG) vaccination as a surrogate for M. tuberculosis infection...
  81. pmc Mycobacterium tuberculosis and the host response
    Stefan H E Kaufmann
    Max Plank Institute for Infection Biology, Berlin D10117, Germany
    J Exp Med 201:1693-7. 2005
    ..tuberculosis and the infected host, the nature of protective immune responses, adaptation of the bacillus to host-imposed stresses, animal models, and new techniques...
  82. ncbi Immunogenicity and protective efficacy of a fusion protein vaccine consisting of antigen Ag85B and HspX against Mycobacterium tuberculosis infection in mice
    Q Li
    Lanzhou Center for Tuberculosis Research and Institute of Pathogenic Biology, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China
    Scand J Immunol 73:568-76. 2011
    ....
  83. ncbi A novel recombinant Mycobacterium bovis bacillus Calmette-Guerin strain expressing human granulocyte macrophage colony-stimulating factor and Mycobacterium tuberculosis early secretory antigenic target 6 complex augments Th1 immunity
    Xiaoling Yang
    Laboratory of Infection and Immunity, School of Basic Medicine, West China Center of Medical Sciences, Sichuan University, Chengdu, China
    Acta Biochim Biophys Sin (Shanghai) 43:511-8. 2011
    ..The data presented here suggested the possibility that the recombinant BCG:GE might be a good vaccine candidate to TB...
  84. pmc Higher human CD4 T cell response to novel Mycobacterium tuberculosis latency associated antigens Rv2660 and Rv2659 in latent infection compared with tuberculosis disease
    Lerisa Govender
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, South Africa
    Vaccine 29:51-7. 2010
    ..Persons with LTBI preferentially recognize Rv2659 and Rv2660, compared with patients with TB disease. These results suggest promise of these antigens for incorporation into post-exposure TB vaccines...
  85. ncbi Recombinant Mycobacterium smegmatis expressing an ESAT6-CFP10 fusion protein induces anti-mycobacterial immune responses and protects against Mycobacterium tuberculosis challenge in mice
    H Zhang
    Laboratory Animal Center, Fourth Military Medical University, Xi an, China
    Scand J Immunol 72:349-57. 2010
    ..S-e6c10 and BCG vaccination was similar based on measures of MTB burden and lung pathology. Our data indicate that the recombinant M. smegmatis vaccine expressing the ESAT6-CFP10 fusion protein has potential in clinic application...
  86. ncbi Respiratory mucosal immunization with adenovirus gene transfer vector induces helper CD4 T cell-independent protective immunity
    Jingyu Mu
    Department of Pathology and Molecular Medicine, Centre for Gene Therapeutics and M G DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, Ontario, Canada
    J Gene Med 12:693-704. 2010
    ..However, whether virus-mediated mucosal immunization can produce immune protective CD8 T cells without the CD4 T cell help remains to be investigated...
  87. ncbi TB vaccines: current status and future perspectives
    Claus Aagaard
    Department of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark
    Immunol Cell Biol 87:279-86. 2009
    ..Three such fusion proteins are currently in clinical trials, the two most advanced have already passed phase I trials and are entering phase II...
  88. pmc CXCR6 is a marker for protective antigen-specific cells in the lungs after intranasal immunization against Mycobacterium tuberculosis
    Lian Ni Lee
    Nuffield Department of Medicine, University of Oxford, The Peter Medawar Building for Pathogen Research, South Parks Road, Oxford OX1 3SY, United Kingdom
    Infect Immun 79:3328-37. 2011
    ....
  89. ncbi Tuberculosis vaccine development; from mouse to man
    Steven Reed
    Infectious Disease Research Institute, 1124 Columbia St, Ste 600, Seattle, WA 98104, USA
    Microbes Infect 7:922-31. 2005
    ..Safety, immunogenicity, and protection studies in mice, guinea pigs, rabbits, and monkeys supported the initiation of clinical development of Mtb72f in AS02A...
  90. ncbi A comparison of IFNgamma detection methods used in tuberculosis vaccine trials
    Natalie E R Beveridge
    Jenner Institute, Old Road Campus Research Building, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7DQ, UK
    Tuberculosis (Edinb) 88:631-40. 2008
    ..Future tuberculosis vaccine trials and immunology studies should ideally include a combination of ex vivo and cultured assays to ensure a thorough and multifaceted evaluation of the immune response is achieved...
  91. pmc Unique model of dormant infection for tuberculosis vaccine development
    Suely S Kashino
    The Forsyth Institute, 140 The Fenway, Boston, MA, 02115 3799, USA
    Clin Vaccine Immunol 13:1014-21. 2006
    ..tuberculosis strain 18b constitutes a simple and attractive animal model for evaluation of antituberculosis vaccines in the context of an M. tuberculosis-presensitized host, a prevailing condition among humans in need of a vaccine...
  92. ncbi Treatment of multi-drug-resistant tuberculosis in mice with DNA vaccines alone or in combination with chemotherapeutic drugs
    Y Liang
    Army Tuberculosis Prevention and Control Key Laboratory, Institute of Tuberculosis Research, the 309th Hospital of Chinese PLA, Beijing, China
    Scand J Immunol 74:42-6. 2011
    ..03-1.38 logs, respectively. Ag85A DNA combined with conventional chemotherapy for the treatment of MDR-TB might result in cure of MDR-TB in developing countries...
  93. ncbi Novel tuberculosis vaccines on the horizon
    Shreemanta K Parida
    Max Planck Institute for Infection Biology, Department of Immunology, Berlin, Germany
    Curr Opin Immunol 22:374-84. 2010
    ..The live mutants of Mycobacterium tuberculosis show great promise, but face a myriad of regulatory challenges...
  94. ncbi Liposome-based cationic adjuvant formulations (CAF): past, present, and future
    Dennis Christensen
    Vaccine Delivery and Formulation, Department Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark
    J Liposome Res 19:2-11. 2009
    ....
  95. ncbi Clinical trials of TB vaccines: harmonization and cooperation
    Hassan Mahomed
    South African TB Vaccine Initiative, University of Cape Town, Cape Town, South Africa
    Tuberculosis (Edinb) 92:S21-4. 2012
    ..Lastly, there needs to be sufficient funding to support TB vaccine development. These challenges can be met through commitment by all role-players within the TB vaccine arena and with support from external stakeholders...
  96. pmc Live attenuated Salmonella vaccines against Mycobacterium tuberculosis with antigen delivery via the type III secretion system
    María Dolores Juárez-Rodríguez
    Center for Infectious Diseases and Vaccinology at Biodesign Institute, Arizona State University, Tempe, Arizona, USA
    Infect Immun 80:798-814. 2012
    ....
  97. ncbi First in humans: a new molecularly defined vaccine shows excellent safety and strong induction of long-lived Mycobacterium tuberculosis-specific Th1-cell like responses
    Tom H M Ottenhoff
    Leiden University Medical Center, Dept of Infectious Diseases, Leiden, The Netherlands
    Hum Vaccin 6:1007-15. 2010
    ..These findings encourage further preclinical and clinical studies with TB subunit vaccines and cellular immunity-stimulating new adjuvants...
  98. ncbi Superexpression of tuberculosis antigens in plant leaves
    Yuri L Dorokhov
    Department of Virology and A N Belozersky Institute of Physico Chemical Biology, Moscow State University, Moscow 119992, Russia
    Tuberculosis (Edinb) 87:218-24. 2007
    ..We propose that the strategy of TB antigens superproduction in a plant might be used as a basis for the creation of prophylactic and therapeutic vaccine against TB...
  99. ncbi Pulmonary delivery of DNA encoding Mycobacterium tuberculosis latency antigen Rv1733c associated to PLGA-PEI nanoparticles enhances T cell responses in a DNA prime/protein boost vaccination regimen in mice
    Maytal Bivas-Benita
    Division of Drug Delivery Technology, Leiden Amsterdam Center for Drug Research, 2300 RA Leiden, The Netherlands
    Vaccine 27:4010-7. 2009
    ..These results confirm that PLGA-PEI np are an efficient DNA vaccine delivery system to enhance T cell responses through pulmonary delivery in a DNA prime/protein boost vaccine regimen...
  100. ncbi Airway luminal T cells: a newcomer on the stage of TB vaccination strategies
    Mangalakumari Jeyanathan
    Centre for Gene Therapeutics, M G DeGroote Institute for Infectious Disease Research, and Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, L8N 3Z5 Canada
    Trends Immunol 31:247-52. 2010
    ..tuberculosis challenge restores protection. We propose that understanding the biology of airway luminal T cells holds important implications for developing effective TB vaccination strategies...
  101. ncbi Tuberculosis in Africa: learning from pathogenesis for biomarker identification
    Stefan H E Kaufmann
    Max Planck Institute for Infection Biology, Department of Immunology, Chariteplatz 1, D 10117 Berlin, Germany
    Cell Host Microbe 4:219-28. 2008
    ..Moreover, we outline our attempts to develop biomarkers, which could help the monitoring of TB clinical trials, provide the basis for new diagnostics, and allow prognosis of outcome of infection and of drug treatment...

Research Grants62

  1. Construction of safe and effective live tuberculosis vaccines
    Steven A Porcelli; Fiscal Year: 2013
    ..The information gained will be applied to the design and construction of better vaccines for the prevention of tuberculosis. ..
  2. Molecular Analysis of Tuberculosis Immunity
    WILLIAM ROBERT JACOBS; Fiscal Year: 2013
    ..PROJECT 1: Title: Genetic Approaches for Improving Tuberculosis Vaccines Project Leader: Jacobs, W...
  3. Defining the Correlates of Bactericidal Immunity in Tuberculosis
    Steven A Porcelli; Fiscal Year: 2012
    ..immune system can control and eliminate Mtb, and have potentially major implications for development of tuberculosis vaccines. PUBLIC HEALTH RELEVANCE: Tuberculosis remains one of the most important global causes of morbidity and ..
  4. Pre-Exposure Prophylaxis Against Francisella tularensis
    MARCUS AARON HORWITZ; Fiscal Year: 2013
    ..vaccines against tuberculosis that are safer and more potent than the current BCG vaccine;one of these tuberculosis vaccines has already demonstrated safety and enhanced immunogenicity in human trials...
  5. Pre-Exposure Prophylaxis Against Francisella tularensis
    MARCUS AARON HORWITZ; Fiscal Year: 2012
    ..vaccines against tuberculosis that are safer and more potent than the current BCG vaccine;one of these tuberculosis vaccines has already demonstrated safety and enhanced immunogenicity in human trials...
  6. Mechanisms of Immune Regulation in Mycobacterium Tuberculosis Infection
    CHERYL LIANE DAY; Fiscal Year: 2012
    ..response fails in some infected individuals who progress to develop active tuberculosis disease;such studies will open up new avenues of research on immunotherapeutic interventions and the design of more effective tuberculosis vaccines.
  7. Community-Based Sites for Evaluation of New TB Vaccines
    LEW M D BARKER; Fiscal Year: 2007
    ..and USPHS agencies convened a workshop to create a national strategy for development of effective tuberculosis vaccines, resulting in a "Blueprint for Tuberculosis Vaccine Development"...
  8. LATENCY AND REACTIVATION TUBERCULOSIS
    YUKARI MANABE; Fiscal Year: 2006
    ..Appropriate animal models are critical to the successful development of tuberculosis vaccines, new drugs and better diagnostic tests for tuberculosis.
  9. Heat Shock Protein based vaccine for Tuberculosis
    ANNIE MO; Fiscal Year: 2003
    ..heat shock protein-peptide complexes to elicit T cell responses may address a shortcoming of traditional tuberculosis vaccines that primarily elicit antibody responses...
  10. TUBERCULOSIS RESEARCH MATERIALS AND VACINE TESTING
    John Belisle; Fiscal Year: 2000
    ..tuberculosis and to provide a facility to evaluate candidate anti-tuberculosis vaccines in animal models...
  11. DEFINED NATIVE ANTIGENS AND IMMUNITY TO TUBERCULOSIS
    Ian Orme; Fiscal Year: 2006
    ..The proposed work will draw upon the broad expertise of various members of the Mycobacteria Research Laboratories at Colorado State University, as well as several eminent consultants and advisers. ..
  12. STRATEGIES FOR TUBERCULOSIS VACCINE DEVELOPMENT AND SCRE
    Ian Orme; Fiscal Year: 2004
    ..abstract_text> ..
  13. Guinea pig model for TB vaccine evaluations
    Ian Orme; Fiscal Year: 2007
    ..The proposed studies are lengthy, and unavoidably expensive, but should provide a basic framework upon which a standardized procedure for efficacy and safety testing of new tuberculosis vaccines can be based. [unreadable] [unreadable]
  14. AGING AND IMMUNITY IN TUBERCULOSIS
    Ian Orme; Fiscal Year: 2002
    ....
  15. Chronic Tuberculosis: Latent or Dynamic
    Ian Orme; Fiscal Year: 2008
    ..unreadable] [unreadable]..
  16. Role of DAP12 in type 1 anti-mycobacterial immunity
    Zhou Xing; Fiscal Year: 2005
    ..We strongly believe that our studies will provide new insights into the mechanisms of type 1 anti-microbial immunity and novel targets for immune modulation. ..
  17. Mechanistic Studies at the Host-pathogen Interface
    David McMurray; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  18. STRUCTURE/FUNCTION RELATIONSHIP FOR ANTIBODIES TO M. TUB
    Aharona Glatman Freedman; Fiscal Year: 2003
    ..This study will help us understand the structural characteristics required for useful antibodies to M. tuberculosis. ..
  19. DIETARY DEFICIENCIES AND TUBERCULOSIS VACCINE EFFICACY
    David McMurray; Fiscal Year: 2009
    ..abstract_text> ..
  20. Novel Approach for Vaccine Development against M.Tb
    Aharona Glatman Freedman; Fiscal Year: 2003
    ..2) To isolate mycobacterial arabinomannan fractions and generate candidate vaccines. 3) To determine the protective efficacy of arabinomannan and arabinomannan-protein conjugate vaccine candidates against Mtb infection. ..
  21. Novel Antimicrobial Agents Against M. tuberculosis
    MARCUS HORWITZ; Fiscal Year: 2008
    ..mammalian GS, and test the toxicity of the analogs in mice. 2) Test the novel MSO analogs for their capacity to inhibit M. tuberculosis growth in broth culture, in human macrophages, and in guinea pigs. ..
  22. TREATMENT OF TUBERCULOSIS WITH IMMUNOMODULATORS
    Samuel Behar; Fiscal Year: 2008
    ..abstract_text> ..
  23. Protective immunity induced by newborn BCG vaccination
    Willem Hanekom; Fiscal Year: 2009
    ..We will characterize this response in newborns vaccinated with BCG. We will compare the antibody response between BCG-vaccinated infants who are protected against TB, and those not protected. ..
  24. A TB Vaccine for AIDS Patients
    MARCUS AARON HORWITZ; Fiscal Year: 2010
    ..Finally, we shall confirm the safety of the new recombinant vaccines in an immunocompromised animal host (SCID mouse model). ..
  25. DEVELOPMENT AND TESTING OF NEW TUBERCULOSIS VACCINES
    MARCUS AARON HORWITZ; Fiscal Year: 2010
    ..tuberculosis. Lay Summary: Tuberculosis is a major worldwide public health problem. This proposal seeks to develop a more potent vaccine with which to combat this disease. ..
  26. Cd1d regulation and its effect on NKT cell activation
    Samuel M Behar; Fiscal Year: 2010
    ....
  27. Antigen-specific CD8+ T cells and protective immunity to tuberculosis
    Samuel M Behar; Fiscal Year: 2010
    ..tuberculosis-specific immune response will also be determined. This proposal will directly assess how CFP10-specific CD8+ T cells contribute to host defense and how their function is modulated by immunity and disease. ..
  28. Characterization of the M. tuberculosis phagosome
    MARCUS HORWITZ; Fiscal Year: 2007
    ..These experiments will advance our understanding of the cell biology and pathogenic mechanisms of M. tuberculosis and facilitate the development of new strategies to combat tuberculosis. [unreadable] [unreadable]..
  29. ROLE OF THE ALPHAE INTEGRIN IN IMMUNITY TO TUBERCULOSIS
    Samuel Behar; Fiscal Year: 2004
    ..tuberculosis is altered in alphaE deficient mice; and 3) Investigate potential mechanisms by which alphaEbeta7 may affect susceptibility to tuberculosis. ..
  30. Vaccine Induced Mucosal Protection Against TB Infection
    DANIEL HOFT; Fiscal Year: 2005
    ..Prime/boosting strategies found to prevent BCG infection after aerosol challenges will be studied for the ability to prevent infection with virulent M. tuberculosis by aerosol challenge. ..
  31. Characterization of the Francisella tularensis phagosome
    MARCUS HORWITZ; Fiscal Year: 2003
    ..tularensis subverts the host cell membrane trafficking pathways and attains an intracellular compartment that is hospitable for its survival and growth will help guide new strategies for the prevention and treatment of tularemia. ..
  32. IMMUNOLOGICAL BASIS OF SUSCEPTIBILITY TO TUBERCULOSIS
    Samuel Behar; Fiscal Year: 2003
    ..Aim 4. Characterize the immune response to tuberculosis in mouse models that simulate the abnormalities of cell mediated immunity typical of HIV/AIDS patients. ..
  33. TREATMENT OF TUBERCULOSIS WITH IMMUNOMODULATORS
    Samuel Behar; Fiscal Year: 2003
    ..We believe that this series of experiments will lay the foundation for the development of a-galactosylceramide as an adjunct therapy for tuberculosis, a treatment that ultimately may be relevant to other infectious diseases as well. ..
  34. TRYPANOSOMA CRUZI MUCOSAL & SYSTEMIC PROTECTIVE IMMUNITY
    DANIEL HOFT; Fiscal Year: 2008
    ..Chemokine and/or integrin receptor expression will be studied by flow cytometry and RT-Real-Time PCR, and the in vivo effects of defective chemokine and integrin binding and/or signaling will be evaluated. [unreadable] [unreadable]..
  35. M TUBERCULOSIS GLUTAMINE SYNTHETASE EXPORT & INHIBITION
    MARCUS HORWITZ; Fiscal Year: 2002
    ..tuberculosis glutamine synthetase, they hope to develop more active entities than the parent compound and thereby to develop a new antibiotic against M. tuberculosis. ..
  36. M TUBERCULOSIS PHAGOSOME
    MARCUS HORWITZ; Fiscal Year: 2002
    ..tuberculosis to survive and multiply within its host cells and should facilitate the development of new strategies for prevention and treatment of tuberculosis. ..
  37. Development & Manufacture of an MDR Tuberculosis Vaccine
    Steven Reed; Fiscal Year: 2005
    ..This will enable us to immediately proceed to human clinical trials after the end of the funding period. ..
  38. Human T Cell Antigens of Mycobacterium tuberculosis
    Steven Reed; Fiscal Year: 2009
    ..Finally, we will test antigens/vaccine formulations in rodent models of infection and disease. By the end of the funding period, we will have defined a second vaccine candidate for entry into clinical trials. ..
  39. TRANSMISSION DYNAMICS OF TB ALONG THE U.S.-MEXICO BORDER
    Peter Barnes; Fiscal Year: 2004
    ..Finally, it will determine if rapid RFLP methods can contribute to TB control efforts. The knowledge gained will permit refinement of TB control strategies along the U.S.-Mexico border and in Latin America. ..
  40. Pathogen-Host Standoff: Persistent and Latent Infection
    Joanne Flynn; Fiscal Year: 2004
    ..This meeting seeks to bring together researchers from a variety of fields, with the common goal of understanding how persistent pathogens survive and how the host responds to such pathogens. ..
  41. The role of IL-12p40 in the response of pulmonary dendritic cells to tuberculosis
    Andrea M Cooper; Fiscal Year: 2010
    ..This increased understanding will allow targeted and novel interventions that will improve our ability to control disease. ..
  42. Prevalence, risk factors and consequences of complex M. Tuberculosis infections
    Theodore Cohen; Fiscal Year: 2010
    ..The overall goal of this study is to learn more about the natural history of TB and to use this knowledge to improve the health of individuals and their communities. ..
  43. Immune cell dynamics during central nervous system viral infection
    Juan C de la Torre; Fiscal Year: 2010
    ..abstract_text> ..
  44. Molecular Epidemiology of Leprosy
    Varalakshmi D Vissa; Fiscal Year: 2010
    ..leprae. ..
  45. Neuroimmunologic Disorders Induced by Chronic Viral Infection
    JUAN DE LA TORRE; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  46. TARGETING DEFENSES OF MYCOBACTERIUM TUBERCULOSIS
    Carl Nathan; Fiscal Year: 2004
    ..abstract_text> ..
  47. Anti-interferon Activity of the Arenavirus Nucleoprotein
    JUAN DE LA TORRE; Fiscal Year: 2008
    ..abstract_text> ..
  48. Impact of chronic infection in the aged on the response to vaccination
    Andrea Cooper; Fiscal Year: 2007
    ..These experiments are relevant to human health since determining the effect of inflammation on the response to vaccination will allow us to improve vaccination in the elderly. [unreadable] [unreadable] [unreadable] [unreadable]..
  49. MACROPHAGES, DENDRITIC CELLS AND PATHOGENS
    Carl Nathan; Fiscal Year: 2007
    ..Cores provide for BSL3 wet lab and mouse work; microarray analysis of gene expression; computation and comparison of gene expression results; and high throughput screening of chemical libraries. ..
  50. Latent and Reactivation Tuberculosis
    Joanne Flynn; Fiscal Year: 2007
    ..These studies are the first to study reactivation in an immunologically tractable animal model that is similar to human latent tuberculosis. ..
  51. Type I Interferons in Immunity to Tuberculosis
    JOEL ERNST; Fiscal Year: 2008
    ..abstract_text> ..
  52. Molecular approaches for understanding TB dynamics
    Theodore Cohen; Fiscal Year: 2008
    ..It is our hope that better analytic techniques will allow for more accurate assessments of treatment and prevention. [unreadable] [unreadable]..
  53. Molecular typing of Mycobacterium leprae
    Varalakshmi Vissa; Fiscal Year: 2005
    ..leprae in the transmission of leprosy via nasal or dermal routes of ntry and release of the pathogen and the differentiation of relapse from reinfection in patients. ..
  54. Identification of Borna Disease Virus Receptor Proteins
    JUAN DE LA TORRE; Fiscal Year: 2006
    ..G*/p56; 3) Determination of expression pattern of BDV candidate receptors in vivo. ..
  55. REVERSE GENETICS OF ARENAVIRUSES
    JUAN DE LA TORRE; Fiscal Year: 2007
    ..We will use biochemical, genetics and functional assays to assess the relevance in Arenavirus biology of candidates initially identified by TAP/MS. ..
  56. Dihydrolipoamide Acyltransferase:Target for Chemotherapy
    Carl Nathan; Fiscal Year: 2004
    ..abstract_text> ..
  57. NATURAL HISTORY OF HEPATITIS C INFECTION IN HIV DISEASE
    C Horsburgh; Fiscal Year: 2003
    ..These studies are expected to improve our understanding of the natural history and pathogenesis of HCV in immunosuppressed hosts. ..
  58. Regulation of IFN-gamma production in human tuberculosis
    Peter Barnes; Fiscal Year: 2009
    ..CREB/ATF/AP-1 levels in T-cells of tuberculosis patients will be enhanced by viral expression vectors and nucleofection, and the effects on IFN-gamma production will be determined. ..
  59. ROLE OF NO SYNTHASE-2 IN MURINE ALZHEIMER'S DISEASE
    Carl Nathan; Fiscal Year: 2004
    ..abstract_text> ..
  60. M. TUBERCULOSIS INFECTION IN THE LUNG
    HENRY BOOM; Fiscal Year: 2010
    ....